IMNM Immunome Inc. Insider Trading

Director Isaac Barchas sells 100,000 shares (100.0K shares) for $2,412,521.54 via pre-arranged 10b5-1 plan

Isaac Barchas executed 2 separate sales totaling 100,000 shares for $2,412,521.54 on 2026-07-06 and 2026-07-07 at blended average price $24.13. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2026-03-31, meaning it was scheduled rather than discretionary. The sale reduced his holdings by 48.0%, from 208,504 shares to 108,504 shares post-transaction. At the same ticker IMNM, Barchas has prior sell history (2025-12-22) with modest 30-day returns (+14.5%, +11.3%) followed by negative 90-day returns (-7.9%, -10.4%), suggesting a pattern of near-term strength followed by longer-term underperformance after his sales. The company context shows material challenges: unprofitable with net income of $-53,839,000.00, full-year negative earnings, revenue of $0.00 in the latest quarter, and annual revenue decline of -23.2%.

CMO Robert Lechleider sells 55,000 shares (77.7% of holdings) at $21.95–$23.44 via scheduled 10b5-1 plan

Robert Lechleider, Chief Medical Officer of Immunome Inc., executed 3 separate sales totaling 55,000 shares for $1,244,330.62 on 2026-07-02 under a pre-arranged 10b5-1 trading plan adopted on 2026-03-26. The sales reduced his non-derivative holdings from 70,805 shares to 15,805 shares, representing a 77.7% reduction, though he retains 290,000 employee stock options. The blended transaction price of $22.62 falls below the current market price of $24.39 and within the stock's 52-week range of $7.96–$27.65. The company remains unprofitable with a net income of -$53,839,000 and negative annual revenue growth of -23.2%, establishing a financially distressed backdrop. Since the transaction is governed by a scheduled 10b5-1 plan rather than discretionary timing, the trade reflects contract-based execution rather than reactive market positioning. Investors should note the substantial reduction in direct share ownership by the CMO while factoring in the non-discretionary nature of the sale.

Director Isaac Barchas sells 201,050 shares ($4.4M) at $21.12–$23.33 via pre-arranged 10b5-1 plan; retains 208,504 shares post-sale.

Director Isaac Barchas executed 3 separate sales totaling 201,050 shares for $4,393,024.30 on June 30 and July 2, 2026, reducing his stake from 409,554 shares to 208,504 shares (a -49.1% reduction in holdings). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-31, meaning the sales were scheduled in advance rather than discretionary. Immunome is unprofitable, with net income of -$53,839,000 over the most recent full fiscal year, annual revenue declined -23.2%, and the company reported $0.00 revenue in the latest quarter. The stock has appreciated +22.1% over the prior 30 days and currently trades at $23.61, though it remains -14.6% below its 52-week high of $27.65. Barchas's cross-ticker track record shows 2 prior open-market sales with an average 90-day return of -9.2%, while his 2 prior sales at IMNM (both on 2025-12-22) posted 90-day returns of -7.9% and -10.4%, suggesting his prior sales at this ticker have been followed by declines. The magnitude of the position reduction (49.1%) and the substantial dollar proceeds ($4.4M) warrant observation in the context of the company's fundamental challenges.

CMO Robert Lechleider sold 55,000 shares (77.7% of holdings) for $1.1M via scheduled 10b5-1 plan at IMNM

Robert Lechleider, Chief Medical Officer at Immunome Inc., executed 2 separate sales totaling 55,000 shares for $1,091,662.00 on 2026-06-25 through a pre-arranged 10b5-1 trading plan adopted 2026-03-26. The transactions reduced his direct shareholdings from 70,805 shares to 15,805 shares, though he retains 345,000 shares through employee stock options. The company is unprofitable (net income of $-53,839,000.00 most recently) with negative annual revenue growth of -23.2%. At the transaction prices (blended average $19.85), Lechleider sold near the current price of $21.04 and within the 52-week range ($7.96–$27.65). As a scheduled 10b5-1 execution, this sale reflects pre-commitment under Rule 10b5-1 mechanics rather than a discretionary market-timing decision.

CFO Max Rosett sold 60,000 IMNM shares ($1.1M) under 10b5-1 plan; stock down 33.0% from 52-week high.

Max Rosett, Chief Financial Officer of Immunome Inc., sold 60,000 shares at $18.23 on 2026-06-15 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-26, reducing his non-derivative holdings to 54,037 shares from 114,037 shares. The sale occurs within a deeply challenged fundamental context: the company reported $0.00 revenue in its latest quarter, a net loss of $-53,839,000.00, and an annual revenue decline of -23.2%. The stock has declined 33.0% from its 52-week high and is down 6.9% over the past 30 days. The transaction is scheduled rather than discretionary, so timing attributions do not apply; however, his prior two same-ticker sales at IMNM on 2026-04-02 (achieving 30-day returns of 3.7% and 1.1%) provide no clear signal of accurate market-timing ability at this ticker. The combination of severe revenue contraction, substantial operating losses, and continued insider stock disposals warrants attention to the company's path to profitability.

Director Jean Jacques Bienaime executed 2 sales and 3 buys on same day (10.5K shares each), net neutral in share count.

On 2026-06-05, Jean Jacques Bienaime (Director) filed 2 separate sales totaling 10,500 shares for $203,820.00 alongside 3 separate purchases totaling 10,500 shares for $204,260.00 at prices ranging from $19.27 to $19.48. The transaction left his holdings unchanged at 43,415 shares while the stock currently trades at $18.39, down 33.5% from its 52-week high of $27.65. At IMNM specifically, Bienaime's 5 prior trades show mixed timing outcomes: 3 of 5 prior buys generated positive 90-day returns, while the stock has declined 18.0% over the past 30 days and 14.1% over the past 90 days. The company reported zero revenue in its latest quarter and net income of $-53,839,000.00.

Director Jean Jacques Bienaime buys 5,000 shares of IMNM at $20.70 on 2026-05-15; stock now -33.5% from 52-week high.

Jean Jacques Bienaime purchased 5,000 shares at $20.70, increasing his holdings by 13.0% to 43.4K shares. The stock has declined -17.2% over 30 days and now trades at $18.38, down -33.5% from its 52-week high of $27.65. The company remains unprofitable, with a most recent quarterly revenue of $0.00 and full-year net income of $-53.8M, reflecting an annual revenue decline of -23.2%. At the same ticker, Bienaime's prior 5 trades show mixed timing: 3 of 5 were well-timed at the 90-day mark, with one prior buy on 2026-03-11 declining -13.6% over 90 days and his most successful trade on 2025-03-25 gaining +12.3%. The current purchase occurs against a backdrop of significant recent weakness and operational challenges.

CFO Rosett Max sold 65,000 shares ($1.4M) via scheduled 10b5-1 plan; retains 54,037 shares post-sale

Rosett Max, Chief Financial Officer of Immunome Inc., executed 2 separate sales totaling 65,000 shares for $1,424,916.08 on 2026-04-02 at a blended average price of $21.92. This represents a 54.6% reduction in his pre-transaction holdings from 119,037 shares to 54,037 shares post-transaction. The sale was conducted pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-12-26, indicating a scheduled disposition rather than a discretionary decision. The magnitude of the reduction—from 119K to 54K shares—reflects a material liquidity event, though the scheduled nature of the plan removes timing-based inference about market outlook.

CEO Siegall purchases 25,450 shares of IMNM at $19.67 for $500.6K; stock now at $21.87, 3 of 5 prior buys well-timed at 90 days.

SIEGALL CLAY B, President and CEO, purchased 25,450 shares at $19.67 on 2026-03-27, increasing holdings from 665.3K to 690.7K shares (+3.8%). The current price of $21.87 represents a gain of approximately 11% from the transaction price. Examining his same-ticker history at IMNM reveals a mixed but notable pattern: of his 5 prior purchases, 3 demonstrated positive 90-day returns (2025-03-26 at +22.4%, 2025-01-31 at +14.3%, and 2025-12-19 at +1.7%), indicating timing acumen in roughly 60% of prior trades. However, the company's fundamentals present a stark counterpoint—the latest quarter showed revenue of $0.00 with a net loss of $-57.5M, annual revenue declined 23.2%, and the company remains unprofitable. The timing pattern of his prior buys at this ticker suggests selective execution, but the severe operational deterioration raises a material disconnect between insider buying activity and underlying business health.

Director WAGENHEIM PHILIP sold 65,000 shares (65.0K shares) at blended $20.55 for $1,335,626.00; holds 341.1K shares post-transaction

Director Philip Wagenheim executed 2 separate sales totaling 65,000 shares for $1,335,626.00 on March 20 and 23, 2026, reducing his stake by 16.0% from 406,147 to 341,147 shares. The sales occurred at prices ($20.47 and $20.65) near current market levels ($20.75 currently, -23.1% from 52-week high of $26.97), suggesting execution without apparent timing advantage relative to recent trading range. Immunome remains unprofitable with net income of $-57,457,000.00 in the most recent period and annual revenue decline of -23.2% year-over-year, creating a backdrop of operational headwinds. The magnitude of the sale—representing a material reduction in insider holdings—warrants attention given the company's negative earnings trajectory, though the sale price's proximity to current market levels and the director's retention of substantial remaining shares provide some context.